Utah Medical Products, Inc. (NASDAQ:UTMD) CEO Kevin L. Cornwell sold 1,100 shares of the business’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $93.97, for a total value of $103,367.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of UTMD stock traded down $1.75 during trading hours on Friday, hitting $96.40. The stock had a trading volume of 20,507 shares, compared to its average volume of 17,581. Utah Medical Products, Inc. has a one year low of $60.15 and a one year high of $101.45. The stock has a market capitalization of $365.18, a price-to-earnings ratio of 25.10 and a beta of 0.59.
Utah Medical Products (NASDAQ:UTMD) last issued its earnings results on Tuesday, January 30th. The medical instruments supplier reported $0.95 earnings per share (EPS) for the quarter. Utah Medical Products had a return on equity of 18.85% and a net margin of 20.54%. The firm had revenue of $10.20 million for the quarter.
The company also recently announced a quarterly dividend, which was paid on Tuesday, April 3rd. Stockholders of record on Friday, March 16th were issued a $0.27 dividend. The ex-dividend date was Thursday, March 15th. This represents a $1.08 annualized dividend and a dividend yield of 1.12%.
Several hedge funds have recently modified their holdings of the company. Thomson Horstmann & Bryant Inc. bought a new stake in Utah Medical Products during the fourth quarter worth approximately $3,543,000. Renaissance Technologies LLC increased its stake in Utah Medical Products by 9.8% during the fourth quarter. Renaissance Technologies LLC now owns 212,200 shares of the medical instruments supplier’s stock worth $17,273,000 after acquiring an additional 18,900 shares during the last quarter. OxFORD Asset Management LLP increased its stake in Utah Medical Products by 274.4% during the third quarter. OxFORD Asset Management LLP now owns 13,781 shares of the medical instruments supplier’s stock worth $1,029,000 after acquiring an additional 10,100 shares during the last quarter. Bailard Inc. bought a new stake in Utah Medical Products during the fourth quarter worth approximately $816,000. Finally, Deutsche Bank AG increased its stake in Utah Medical Products by 39.7% during the fourth quarter. Deutsche Bank AG now owns 24,659 shares of the medical instruments supplier’s stock worth $2,005,000 after acquiring an additional 7,002 shares during the last quarter. 67.12% of the stock is currently owned by hedge funds and other institutional investors.
Separately, BidaskClub downgraded Utah Medical Products from a “strong-buy” rating to a “buy” rating in a research report on Wednesday.
WARNING: “Utah Medical Products, Inc. (NASDAQ:UTMD) CEO Sells $103,367.00 in Stock” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/kevin-l-cornwell-sells-1100-shares-of-utah-medical-products-inc-utmd-stock.html.
Utah Medical Products Company Profile
Utah Medical Products, Inc develops, manufactures, and distributes medical devices for the healthcare industry worldwide. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD, an infant respiratory hood; and DELTRAN PLUS, a blood pressure monitoring system.
Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.